The two drugs were previously approved by the FDA for Type 2 diabetes treatment in adults in 2014 and 2015 respectively. However, since 2000, children with the condition have only had one available oral-treatment option: Metformin — until now.
“Compared to adults, children with Type 2 diabetes have limited treatment options, even though the disease and symptom onset generally progress more rapidly in children,” Michelle Carey, MD, director of therapeutic review for the FDA’s Division of Diabetes, Lipid Disorders, and Obesity said in a statement. “Today’s approvals provide much-needed additional treatment options for children with Type 2 diabetes.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
